| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
543,060,000 |
| Market
Cap: |
2.07(B) |
| Last
Volume: |
6,922,219 |
Avg
Vol: |
4,631,321 |
| 52
Week Range: |
$1.74 - $4.14 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Geron is a biopharmaceutical company that is focused on the development and commercialization of imetelstat, a telomerase inhibitor. Co. is conducting two ongoing Phase 3 clinical trials that are designed to enable registration of imetelstat: (i) IMerge Phase 3 in lower risk myelodysplastic syndromes (MDS), and (ii) IMpactMF in refractory myelofibrosis (MF). Imetelstat has been granted Fast Track designations by the U.S. Food and Drug Administration for the treatment of patients with transfusion-dependent anemia due to lower risk MDS and who are refractory or resistant to treatment with an erythropoiesis stimulating agent and for the treatment of patients with MF.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
13,186 |
13,186 |
| Total Buy Value |
$0 |
$0 |
$30,064 |
$30,064 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
2,194,719 |
| Total Sell Value |
$0 |
$0 |
$0 |
$6,658,632 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
7 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Earp David |
SVP Bus Dev, Chief Patnt Couns |
• – – |
2009-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
191,251 |
|
- |
|
| Earp David |
SVP Bus Dev, Chief Patnt Couns |
• – – |
2009-05-29 |
4 |
S |
$6.35 |
$14,459 |
D/D |
(2,277) |
126,251 |
|
- |
|
| Spink Katharine E. |
VP Operations, Regen Med Progs |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$19,332 |
D/D |
(2,864) |
10,542 |
|
- |
|
| Lebkowski Jane |
SVP, CSO Regen Med |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$95,121 |
D/D |
(14,092) |
122,121 |
|
- |
|
| Earp David |
SVP Bus Dev, Chief Patnt Couns |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$104,328 |
D/D |
(15,456) |
128,528 |
|
- |
|
| Kelly Melissa |
SVP Oncology |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$46,028 |
D/D |
(6,819) |
61,278 |
|
- |
|
| Greenwood David |
EVP and CFO |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$130,410 |
D/D |
(19,320) |
156,663 |
|
- |
|
| Okarma Thomas |
President and CEO |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$315,016 |
D/D |
(46,669) |
306,433 |
|
- |
|
| Harley Calvin |
VP, CSO Telomerase Tech |
• – – |
2009-05-26 |
4 |
S |
$6.75 |
$67,507 |
D/D |
(10,001) |
71,313 |
|
- |
|
| Kelsey Stephen Michael |
EVP, CMO, OncologyOfficer |
• – – |
2009-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,000 |
|
- |
|
| Benedetti Fabio M |
SVP, Chief Med Off, Oncology |
• – – |
2009-04-03 |
4 |
S |
$4.44 |
$23,066 |
D/D |
(5,195) |
40,337 |
|
- |
|
| Spink Katharine E. |
VP Ops, Regen Med ProgramsOffi |
• – – |
2009-02-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,406 |
|
- |
|
| Kelly Melissa |
SVP Oncology |
• – – |
2009-02-02 |
4 |
S |
$8.12 |
$119,892 |
I/I |
(14,765) |
0 |
|
- |
|
| Walker John Peter |
Director |
– • – |
2009-01-30 |
4 |
S |
$8.28 |
$402,549 |
D/D |
(48,617) |
39,119 |
|
- |
|
| Walker John Peter |
Director |
– • – |
2009-01-30 |
4 |
OE |
$3.97 |
$229,084 |
D/D |
48,617 |
87,736 |
|
- |
|
| Harley Calvin |
VP and CSO |
• – – |
2009-01-29 |
4 |
S |
$7.08 |
$216,191 |
D/D |
(30,489) |
99,157 |
|
- |
|
| Lebkowski Jane |
SVP, CSO Regen Med |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$19,029 |
I/I |
3,948 |
17,641 |
|
- |
|
| Earp David |
SVP Bus Dev, Chief Patnt Couns |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$14,388 |
I/I |
2,985 |
14,765 |
|
- |
|
| Greenwood David |
EVP and CFO |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$19,029 |
I/I |
3,948 |
7,525 |
|
- |
|
| Benedetti Fabio M |
SVP, Chief Med Off, Oncology |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$14,388 |
I/I |
2,985 |
2,985 |
|
- |
|
| Kelly Melissa |
SVP Oncology |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$14,388 |
I/I |
2,985 |
14,765 |
|
- |
|
| Harley Calvin |
VP and CSO |
• – – |
2009-01-23 |
4 |
A |
$4.82 |
$19,029 |
I/I |
3,948 |
129,646 |
|
- |
|
| Harley Calvin |
VP and CSO |
• – – |
2009-01-05 |
4 |
S |
$4.90 |
$43,419 |
D/D |
(8,861) |
125,698 |
|
- |
|
| Okarma Thomas |
President and CEO |
• – – |
2009-01-05 |
4 |
S |
$4.90 |
$61,309 |
D/D |
(12,512) |
353,102 |
|
- |
|
| Lebkowski Jane |
SVP Regen Medicine |
• – – |
2009-01-05 |
4 |
S |
$4.90 |
$43,419 |
D/D |
(8,861) |
149,906 |
|
- |
|
469 Records found
|
|
Page 12 of 19 |
|
|
0.09 (2.31%) 
